论文部分内容阅读
选取已经接受至少3个月门冬胰岛素30注射液每日2次治疗的2型糖尿病患者30例,联合口服阿卡波糖2周,联合前后采用动态血糖检测的方法,计算血糖变异指标、平均血糖、低血糖人次、空腹及餐后平均血糖情况,评价联合治疗前后患者血糖波动情况、低血糖发生率及日均胰岛素用量的差异。结果联合阿卡波糖治疗后,平均血糖波动幅度、平均血糖水平、血糖最高值、平均餐后血糖均低于联合治疗前,血糖最低值高于治疗前,差异具有统计学意义(P<0.05),低血糖事件少于联合治疗前,差异具有统计学意义(P<0.05),日均胰岛素量和血糖标准差较前减少,但差异无统计学意义(P>0.05)。结论接受门冬胰岛素30注射液每日2次治疗的2型糖尿病患者,联合使用阿卡波糖可以减少血糖变异性,增加血糖稳定性,降低低血糖风险,减少胰岛素用量。
Thirty patients with type 2 diabetes who had received at least 3 months of insulin aspart 30 injection twice daily were enrolled in this study. Acarbose plus oral glucose was given for 2 weeks. Before and after the combination therapy, Blood sugar, hypoglycemia, average fasting and average postprandial blood glucose, evaluate the patients before and after treatment of blood glucose fluctuations, the incidence of hypoglycemia and the average daily dose of insulin. Results After the combination of acarbose treatment, the mean blood glucose fluctuation, mean blood glucose level, the highest value of blood sugar and mean postprandial blood glucose were all lower than those before the combination therapy, with the lowest value of blood glucose being higher than that before treatment (P <0.05 ), And the incidence of hypoglycemia was less than that before treatment (P <0.05). The mean daily insulin amount and standard deviation of blood glucose were significantly lower than those before treatment, but the difference was not statistically significant (P> 0.05). Conclusions Patients with type 2 diabetes treated with insulin aspart 30 injection twice daily can reduce blood glucose variability, increase blood glucose stability, reduce the risk of hypoglycemia, and reduce insulin dosage in combination with acarbose.